Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications.

ABSTRACT

INTRODUCTION: Adiponectin, resistin and leptin belong to adipokines, a group of molecules secreted mainly by the adipose tissue, which impaired expression may be a missing link between various manifestations of systemic sclerosis. Adiponectin, which is also released in small amounts by the endothelium, possesses anti-inflammatory, anti-fibrotic and protective against endothelial injury properties. Both leptin and resistin exhibit features which are contradictory to adiponectin, as they trigger inflammation and the activation of skin fibroblasts. Epoprostenol is a prostaglandin analogue with powerful vasodilator activity and inhibitory effect on platelet aggregation. The aim of the study was to evaluate whether epoprostenol may have an effect on serum adipokine levels in patients with systemic sclerosis. METHODS: A total of 27 patients were included in the study and received epoprostenol intravenously (25 µg of per day for 3 consecutive days). Serum concentrations of total adiponectin, resistin and leptin were assessed with enzyme-linked immunosorbent essay (R&D Systems, Minneapolis, MN, USA). RESULTS: In all SSc patients, the basal level of adiponectin was significantly lower compared to healthy controls (mean 6.00 [Formula see text] 2.81 µg/ml vs. 8.8 [Formula see text] 4.3 µg/ml, p = 0.02) and basal level of resistin (mean 11.12 [Formula see text] 3.36 ng/ml vs. 8.54 [Formula see text] 3.07 ng/ml p = 0.02) was significantly higher than in the control group. The serum concentration of adiponectin increased significantly after treatment with epoprostenol (6.00 [Formula see text] 2.81 µg/ml vs 9.29 [Formula see text] 6.05 µg/ml; P = 0.002). The level of resistin and leptin remained unchanged. CONCLUSION: Epoprostenol infusions up-regulate the serum concentration of adiponectin in patients with systemic sclerosis. In our opinion, future studies on treatments in systemic sclerosis should address the issue of their effect on adipokine metabolism.